North American Cannabis Retail Sales are set to Grow as Cannabis Consumption Increases

NEW YORK, October 24, 2018 /PRNewswire/ --

According to a research report from Marijuana Business Daily, cannabis retail sales continued to increase year-over-year as more states legalized cannabis products for both medical and recreational purposes. Sales in 2018 are projected to increase by approximately 50% when compared to 2017. Sales value is also on track to reach USD 8 Billion - USD 10 Billion by the end of 2018. Additionally, the report specifies that by 2022, annual retail cannabis sales in the United States could exceed the USD 20 Billion mark, representing a 200% surge from 2017. Legal cannabis markets are presently on the rise in major states such as California, Nevada, Colorado and Washington, amongst others. Chemesis International Inc. (OTC: CADMF), AXIM® Biotechnologies, Inc. (OTC: AXIM), Vitality Biopharma, Inc. (OTC: VBIO), Namaste Technologies Inc. (OTC: NXTTF), General Cannabis Corp. (OTC: CANN)

North America is projected to be the biggest market for legal cannabis, as Canada's new laws, officially making cannabis products legal, are expected to create a pioneering business environment. According to another report from Deloitte, the total cannabis market in Canada is expected to generate up to USD 7.17 Billion in total sales in 2019, with up to USD 4.34 Billion coming from the legal channel. Cannabis consumption through legal channels is expected to increase by up to 35%.

Chemesis International Inc. (OTC: CADMF) is also listed on the Canadian Securities Exchange under the ticker (CSE: CSI). Earlier last week, the Company announced that, "its intention to enter the recreational and medical cannabis market in Canada. The Company is reviewing possible joint ventures, agreements or acquisitions in distribution, manufacturing, and product development spaces. Chemesis intends on leveraging its assets, brands, and management expertise to gain market share in Canada. Chemesis is presently performing due diligence on fully licensed and operational cannabis companies in Canada.

Canada has significant opportunity in both recreational and medical markets, with the Canadian cannabis market expected to generate up to $7.17 billion CDN in 20191. The Company sees major opportunities in Canada from high-quality manufacturing to brands that have developed a strong presence in the market. Chemesis aims to introduce Canadian consumers its portfolio of brands which includes California Sap, the Company's flagship brand. California Sap has been recognized in California since 2012, with 25 gold rankings for best CO², best topical, best product, best concentrate, best cartridge, highest terpene and more.

'The Company is looking at multiple opportunities in Canada that will allow us to enter the market and gain a strong presence with minimal regulatory hurdles,' said CEO, Edgar Montero. 'Chemesis is only evaluating businesses that have met regulatory and compliance standards. This allows the Company to enter into the market with our assets, and expertise without unnecessary delay. The introduction of California Sap and our other brands will allow Canadians the ability to purchase premium brands, that are extremely accomplished in California. As we continue to execute our business plan, Chemesis will look for acquisitions and partnerships that bring growth and shareholder value.'"

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) is an innovative biotechnology and pharmaceutical company focusing on research, development and production of cannabinoid-based pharmaceutical and nutraceutical products. Recently, the Company announced that the United States Patent and Trademark Office (USPTO) has issued a patent (US 10,092,538 B2) on a suppository composition comprising cannabinoids developed by the Company. The Company's proprietary suppository composition is formulated for easy absorption through the mucosal membrane, allowing for useful administration of cannabinoids in patients with pain, nausea, vomiting, and other conditions preventing swallowing, or conditions wherein suppository administration is required. Most significantly, AXIM plans to utilize this formulation for use in its clinical program that aims to treat gastrointestinal (GI) conditions such as post-operative ileus and/or Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), and others. AXIM is currently contemplating continuous clinical trials at the University of Wageningen in the Netherlands for treatment of indications such as IBD and IBS with the Company's cannabinoid- based suppository product and CanChew® Rx CBD (cannabidiol) functional, controlled release chewing gum.

Vitality Biopharma, Inc. (OTCQB: VBIO) is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Earlier this month, the Company announced the filing of national patent applications in the United States and Canada that describe compounds discovered to be effective in a drug screening model for neural repair. The discoveries included a compound that is known to have a positive track record of safety in clinical trials and to provide pain relief through modulation of the vanilloid TRPV1 receptor. Cannabidiol (CBD), a non-intoxicating cannabinoid independently FDA-approved in pharmaceutical form for the treatment of epilepsy, is also known to relieve pain through modulation of the TRPV1 receptor. As a result, Vitality has made broad patent claims covering use of CBD and other TRPV1 agonists for myelin repair and for treatment of demyelinating disorders.

Namaste Technologies Inc. (OTCQB: NXTTF) operates the largest global cannabis e-commerce platform with over 30 websites in 20+ countries under various brands. Namaste's product offering through its subsidiaries includes vaporizers, glassware, accessories, CBD products, and the Company will soon be selling medical cannabis through its wholly owned subsidiary CannMart in the Canadian market. Recently, the Company announced that the Company's wholly-owned subsidiary, Cannmart Inc., has received its Access to Cannabis for Medical Purposes Regulations ("ACMPR") medical cannabis "sales-only" license with no cultivation, which is the first of its kind to be issued by Health Canada. The Sales License represents the most significant milestone in the history of the Company and is the final component of its strategy for Cannmart to become Canada's leading online platform for medical cannabis. Cannmart will operate as an online marketplace for medical cannabis sourced from multiple Licensed Producers, which will offer patients a curated selection of medical cannabis strains in one location.

General Cannabis Corp. (OTCQX: CANN) is the comprehensive national resource for the highest-quality service providers available to the regulated cannabis industry. As the legal cannabis industry grows throughout the United States, the industry's leading service provider, General Cannabis Corp. recently announced it is expanding its presence on the East Coast with the opening of a New York office. The New York office provides General Cannabis a strategic location to better serve existing East Coast clients while also attracting new talent and partnerships as the cannabis market in the eastern U.S. continues to develop. Further, the opening of the New York office provides a hub for current clients looking for East Coast expansion opportunities. "Given our growing list of East Coast clients and the steps that states like Massachusetts and New Jersey have taken toward launching adult-use sales, this is the ideal time for General Cannabis to further invest and establish itself in the region," said Michael Feinsod, Executive Chairman of the Board for General Cannabis. "The growth potential for the market in this region is unparalleled. An East Coast office is perfectly suited to cater to this territory as General Cannabis continues to expand its presence nationwide. We plan on expanding our security, operations and marketing segments aggressively throughout the East Coast. In addition, we will be utilizing this office to expand and enhance our corporate, marketing and mergers and acquisitions teams."

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For chemesis international inc. financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .

For further information:

Media Contact:
[email protected]
+1-877-601-1879

Url: www.FinancialBuzz.com

SOURCE FinancialBuzz.com